uploads/2016/08/Chart-05-Cardio-1.jpg

Cialis Continues to Lead in Eli Lilly’s Cardiovascular Franchise

By

Updated

Cardiovascular franchise

Eli Lilly and Co.’s (LLY) cardiovascular franchise includes drugs like Cialis, Effient, Adcirca, and Reopro.

Article continues below advertisement

Effient

Effient is an antiplatelet used with aspirin to prevent blood clots in arteries and stents. It reduces the chances of heart-related events for patients with acute coronary syndrome. Effient sales increased by nearly 5% to $135 million in 2Q16—compared to ~$129 million in 2Q15. This included an increase of 14% in US markets and a decrease of ~32% in international sales.

Cialis

Cialis is a drug that treats erectile dysfunction and benign prostatic hyperplasia. Cialis sales increased by over 11% to $631 million during 2Q16—compared to $568 million for 2Q15. This included an increase of 24% in US markets and a decrease of ~4% in international sales. The sales in US markets were driven by higher realized prices, while the sales in international markets fell due to lower volumes. Cialis competes with Pfizer’s (PFE) Viagra, Auxilium’s (AUXL) Stendra, and GlaxoSmithKline (GSK) and Bayer’s Levitra.

Other drugs in the cardiovascular franchise

Other drugs in the cardiovascular franchise are Adcirca and Reopro. Adcirca is the same as Cialis, but it’s used for pulmonary arterial hypertension. Reopro is a glycoprotein inhibitor injection used to prevent blood clots in arteries for patients with acute coronary syndrome. Reopro is manufactured by Janssen Biologics, a Johnson & Johnson (JNJ) company, but it’s marketed by Eli Lilly.

Investors can consider ETFs like the SPDR S&P Pharmaceuticals ETF (XPH). XPH has invested 4.8% of its portfolio in Eli Lilly. The iShares US Healthcare ETF (IYH) holds ~2.6% of its total assets in Eli Lilly.

Advertisement

More From Market Realist